Immunotherapy drug effective for metastatic triple negative breast cancer

(NYU Langone Medical Center / New York University School of Medicine) The immunotherapy drug, Pembrolizumab, is effective in shrinking tumors among metastatic triple negative breast cancer patients as found in a clinical trial led by NYU Langone's Perlmutter Cancer Center.